mbt italia Osteopontin expression and breast cance

43nike9485qt · Wysłany: Nie 11:35, 20 Mar 2011

Osteopontin expression and breast cancer research progress

Local control rate, the line may need to mastectomy patients with breast-conserving opportunities; and enable some of the treatment of locally advanced inoperable breast cancer into a viable surgical treatment of tumors, to provide treatment to improve the opportunities for advanced breast cancer; and can already exists in vivo inhibition of micrometastasis; Neoadjuvant endocrine therapy can also provide the tumor sensitivity to the hormone valuable information to be effective in guiding adjuvant therapy. NAET fewer side effects, a potential advantage is sustainable use in the perioperative period. In addition,[link widoczny dla zalogowanych], one of the advantages NAET theory - along with the cell biology of endocrine changes in the treatment of metastatic potential can be reduced. Present the view that adaptation to breast cancer NAET targets: ER-positive and (or) PR positive tumors, locally advanced breast cancer or possible breast cancer surgery need to drop a huge period of post-menopausal breast cancer before menopause or unwilling to neoadjuvant chemotherapy should not be breast cancer and breast cancer patients aged over 70 years of age. In this paper, NAET and its progress reviewed. 1NAET theoretical basis for more than a century, mastectomy is the surgical treatment of the classic means of breast cancer, until a large number of randomized clinical trials outcome, was established breast-conserving surgery with or without radiation therapy. This treatment model and the same overall survival for mastectomy, and breast-conserving surgery and radiotherapy can also reduce breast cancer recurrence. Of early breast cancer,[link widoczny dla zalogowanych], breast-conserving surgery plus radiotherapy as the preferred surgical treatment. However, not all such patients to adapt to this treatment program, one of the reasons is due to tumor size or tumor size larger proportion of breast-conserving surgery and not the line. In this case, can not completely remove the breast primary tumor. Therefore, such patients can use neoadjuvant systemic therapy, can reduce the primary tumor, thus improving the success rate of breast-conserving surgery, or to those who can not breast cancer surgery feasible surgery. [Received Date] 2008-06-27 [Author] Bengbu Medical College, Department of Oncology, First Affiliated Hospital of Bengbu, Anhui 233004 [Author] Wang Junbin (1979), male,[link widoczny dla zalogowanych], graduate. * Review of a number of studies have shown that neoadjuvant chemotherapy for breast cancer treatment a standard of care, and compared with the adjuvant treatment of certain potential advantages. However, the efficacy of neoadjuvant chemotherapy in primary tumors rely on a good difference between the hormone receptor, of which evaluate the efficacy of the measures included clinical remission rate and pathological complete response rate (pCR). Compared with ER-negative breast cancer patients, neoadjuvant chemotherapy, the efficacy of low ER-positive patients, the German Breast Cancer Study Group confirmed this conclusion, ER-positive and ER negative pCR were 6.2% and 22.8% . Guameri Neoadjuvant endocrine therapy was more widespread concern. At present, a large number of experimental studies have assessed the efficacy of NAET. Mathew such reports, NAET of ER-positive locally advanced primary breast cancer (1ocallyadvancedprimarybreastcancer, LAPC) has an excellent survival rate, is other treatment modalities in a very good choice. 2 neoadjuvant endocrine therapy clinical drug resistance to estrogen 2.1.1TAMTAM 2.1 is a selective estrogen receptor modulator, competitive with the cancer cells by estrogen binding, and ultimately inhibit tumor growth. In addition, TAM is closely related with many biochemical changes, including calcium channel antagonist, and protein kinase interactions, inhibit blood vessel formation and secretion of transforming growth factor 8. At present, evaluation of TAM neoadjuvant treatment of breast cancer in elderly reported. will take a separate TAM and breast modified radical mastectomy compared with a median follow-up about l0 years, of which TAM taken alone group, tumor progression and disease-free survival time was significantly shorter , while the higher rate of local progress. And the TAM + TAM with radical mastectomy compared with a median follow-up 12.7 years, TAM alone group,[link widoczny dla zalogowanych], total mortality and death due to breast cancer mortality was significantly higher than that of the breast radical surgery and local recurrence rate is also high. These two studies show that TAM alone will produce an unacceptable rate and recurrence rate of local progress. And they are intrinsically linked to experimental design, that TAM treatment alone No surgery, emphasizing the TAM as NAET must be added to improve the efficacy of surgical treatment. 2.1.2 Fulvestrant (fu | vestrant) Fulvestrant is as NAET
More articles related to topics：

[link widoczny dla zalogowanych]

ghd australia Transanal resection of stage Ⅰ Hirs

[link widoczny dla zalogowanych]